These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 28807533)

  • 1. Evaluation of the Effects of Prostate Radiation Therapy on Occludin Expression and Ultrasonography Characteristics of the Bladder.
    Baradaran-Ghahfarokhi M; Amouheidari A; Shahbazi-Gahrouei D; Baradaran-Ghahfarokhi HR; Tanderup K; Dörr W; Shokrani P
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):963-971. PubMed ID: 28807533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
    Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade toxicity after conformal radiation therapy for prostate cancer--impact of bladder volume.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Eble MJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):835-41. PubMed ID: 16289911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.
    Bruner DW; Hunt D; Michalski JM; Bosch WR; Galvin JM; Amin M; Xiao C; Bahary JP; Patel M; Chafe S; Rodrigues G; Lau H; Duclos M; Baikadi M; Deshmukh S; Sandler HM
    Cancer; 2015 Jul; 121(14):2422-30. PubMed ID: 25847819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer.
    Hanssen S; Norum J
    Anticancer Res; 2008; 28(5B):2865-8. PubMed ID: 19031926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
    Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
    Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
    Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics.
    Heemsbergen WD; Al-Mamgani A; Witte MG; van Herk M; Pos FJ; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):19-25. PubMed ID: 20056354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique.
    Fransson P; Bergström P; Löfroth PO; Widmark A
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):430-8. PubMed ID: 16904846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery.
    Ghilezan M; Yan D; Liang J; Jaffray D; Wong J; Martinez A
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1602-10. PubMed ID: 15590192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.